Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2654-2663

  Abram, Michael E ^a   Hluhanich, Rebecca M ^a   Goodman, Derrick D ^a   Andreatta, Kristen N ^a   Margot, Nicolas A ^a   Ye, Linda ^a   Niedziela Majka, Anita ^a   Barnes, Tiffany L ^a   Novikov, Nikolai ^a   Chen, Xiaowu ^a   Svarovskaia, Evguenia S ^a   McColl, Damian J ^a   White, Kirsten L ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CROSS RESISTANCE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

CELL LINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEK293 CELLS; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLONES; VIRUS REPLICATION;

EID: 84877843704     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02568-12     Document Type: Article

References (57)

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 308:387-402.
2. Sakai H, Kawamura M, Sakuragi J, Sakuragi S, Shibata R, Ishimoto A, Ono N, Ueda S, Adachi A. 1993. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 67:1169-1174.
3. Engelman A, Mizuuchi K, Craigie R. 1991. HIV-1 DNA integration: Mechanism of viralDNAcleavage andDNAstrand transfer. Cell 67:1211-1221.
4. Eron JJ, Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY. 2011. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect. Dis. 11:907-915.
5. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY. 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin. Infect. Dis. 50:605-612.
6. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK. 2012. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379:2439-2448.
7. DeJesus E, Rockstroh J, Henry K, Molina J-M, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP. 2012. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet 379:2429-2438.
8. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S. 2012. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviralnaive adults with HIV: Planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect. Dis. 12:111-118.
9. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL. 2012. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatmentexperienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study. Lancet Infect. Dis. 12:27-35.
10. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S, Hertogs K. 2008. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 82:10366-10374.
11. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
12. Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL, Miller MD. 2012. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 93:288-296.
13. Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, Gurnari C, Pannecouque C, De Maeyer M, Engelborghs Y, De Clercq E, Debyser Z, Witvrouw M. 2003. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77:11459-11470.
14. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
15. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55:813-821.
16. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, Huang W. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
17. Cooper DA, Steigbigel RT, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar P, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen B. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
18. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, Parkin NT, Huang W. 2008. Abstr. XVII Int. HIV Drug Resist. Workshop, Sitges, Spain, abstr 7.
19. Waters JM, Margot N, Hluhanich R, Svarovskaia J, Harris J, Borroto-Esoda K, Miller MD, McColl DJ. 2009. Abstr. XVIII Int. HIV Drug Resist. Workshop, Fort Myers, FL, abstr 116.
20. Winters MA, Lloyd RM, Jr, Shafer RW, Kozal MJ, Miller MD, Holodniy M. 2012. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One 7:e40514. doi:10.1371/journal.pone.0040514.
21. Goodman DD, Hluhanich R, Waters JM, Margot NA, Fransen S, Gupta S, Huang W, Parkin N, Borroto-Esoda K, Svarovskaia ES, Miller MD, McColl DJ. 2008. Abstr. XVII Int. HIV Drug Resist. Workshop, Stiges, Spain, abstr 13.
22. Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, Huang W, Hung M, Samuel D, Novikov N, Xu Y, Mitchell M, Guo H, Babaoglu K, Liu X, Geleziunas R, Sakowicz R. 2012. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J. Biol. Chem. 287:21189-21203.
23. Tsiang M, Jones GS, Hung M, Mukund S, Han B, Liu X, Babaoglu K, Lansdon E, Chen X, Todd J, Cai T, Pagratis N, Sakowicz R, Geleziunas R. 2009. Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex. J. Biol. Chem. 284:33580-33599.
24. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
25. Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD. 2008. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48:428-436.
26. Moser MJ, Ruckstuhl M, Larsen CA, Swearingen AJ, Kozlowski M, Bassit L, Sharma PL, Schinazi RF, Prudent Jr. 2005. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49:3334-3340.
27. Wu H, Huang Y, Dykes C, Liu D, Ma J, Perelson AS, Demeter LM. 2006. Modeling and estimation of replication fitness of human immuno-deficiency virus type 1 in vitro experiments by using a growth competition assay. J. Virol. 80:2380-2389.
28. Wang Y, Klock H, Yin H, Wolff K, Bieza K, Niswonger K, Matzen J, Gunderson D, Hale J, Lesley S, Kuhen K, Caldwell J, Brinker A. 2005. Homogeneous high-throughput screening assays for HIV-1 integrase 3betaprocessing and strand transfer activities. J. Biomol. Screen. 10:456-462.
29. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236.
30. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47:9345-9354.
31. Metifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y. 2011. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25:1175-1178.
32. Reigadas S, Masquelier B, Calmels C, Laguerre M, Lazaro E, Vandenhende M, Neau D, Fleury H, Andreola ML. 2011. Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A. Antimicrob. Agents Chemother. 55:3187-3194.
33. Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. 2011. Structural and functional analyses of the secondgeneration integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol. 80:565-572.
34. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. U. S. A. 107: 20057-20062.
35. McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, Hluhanich R, Chen X, Chuck S, Cheng AK, Miller MD. 2007. Abstr. 11th Eur. AIDS Conf., Madrid, Spain, abstr P7.1/03.
36. McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, Ledford R, Chen J, Chuck S, Cheng AK, Miller MD. 2007. Abstr. 16th Int. HIV Drug Resist. Workshop, Bridgetown, Barbados, abstr 9.
37. Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF. 2010. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob. Agents Chemother. 54:3938-3948.
38. Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A, Piketty C. 2008. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 9:765-770.
39. Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N. 2009. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23:455-460.
40. Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, Parissi V, Fleury H, Andreola ML. 2010. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions. PLoS One 5:e10311. doi:10.1371/journal.pone.0010311.
41. Cooper DA, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, Chen J, Isaacs R, Teppler H, Nguyen B-Y. 2007. Abstr. 14th Conf. Retroviruses Opportun. Infect., Los Angeles, CA, abstr 105aLB.
42. Steigbigel R, Kumar P, Eron JJ, Schechter M, Markowitz M, Loutfy M, Zhao J, Isaacs R, Nguyen B-Y, Teppler H. 2007. Abstr. 14th Conf. Retroviruses Opportun. Infect., Los Angeles, CA, abstr 105bLB.
43. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, III, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55:4552-4559.
44. Seki T, Kobayashi M, Wakasa-Morimoto C, Yoshinaga T, Sato A, Fujiwara T, Underwood MR, Garvey EP, Johns BA. 2010. Abstr. 17th Conf. Retroviruses Opportun. Infect., San Francisco, CA, abstr 555.
45. DeJesus E, Cohen C, Elion R, Ortiz R, Maroldo L, Franson S, Pesano R. 2007. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathog. Treat., Sydney, Australia, abstr TUPEB032.
46. Vavro CL, Dudas KC, Hasan S, Huang JO, Yeo JM, Underwood MR. 2012. Dolutegravir treatment of HIV subjects with raltegravir resistance: Integrase resistance evolution in cohort II of the VIKING study. Antivir. Ther. 17:A13.
47. Weber J, Rose JD, Wylie D, Vazquez AC, Rhea AM, Winner D, Margot N, McColl D, Miller M, Quinones-Mateu ME. 2010. Resistance mutations in protease, reverse transcriptase and integrase genes: Do they have an epistatic effect on drug susceptibility and/or HIV-1 replicative fitness? Antivir. Ther. 15:A94.
48. Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, Kanamori-Koyama M, Kawauchi S, Suyama A, Fujishita T, Yoshinaga T, Garvey EP, Johns BA, Foster SA, Underwood MR, Sato A, Fujiwara T. 2009. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 81:141-146.
49. Buzon MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J, Cabrera C. 2008. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antivir. Ther. 13:881-893.
50. Quercia R, Dam E, Perez-Bercoff D, Clavel F. 2009. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J. Virol. 83: 10245-10249.
51. Hu Z, Kuritzkes DR. 2010. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J. Acquir. Immune Defic. Syndr. 55:148-155.
52. Mukherjee R, Jensen ST, Male F, Bittinger K, Hodinka RL, Miller MD, Bushman FD. 2011. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 25:1951-1959.
53. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 37:1193-1201.
54. Dicker IB, Samanta HK, Li Z, Hong Y, Tian Y, Banville J, Remillard RR, Walker MA, Langley DR, Krystal M. 2007. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J. Biol. Chem. 282:31186-31196.
55. Johnson AA, Santos W, Pais GC, Marchand C, Amin R, Burke TR, Jr, Verdine G, Pommier Y. 2006. Integration requires a specific interaction of the donor DNA terminal 5=-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J. Biol. Chem. 281:461-467.
56. Gerton JL, Ohgi S, Olsen M, DeRisi J, Brown PO. 1998. Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions. J. Virol. 72:5046-5055.
57. Khan E, Mack JP, Katz RA, Kulkosky J, Skalka AM. 1991. Retroviral integrase domains: DNA binding and the recognition of LTR sequences. Nucleic Acids Res. 19:851-860.